Edition:
United Kingdom

Michael Erman

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

13 Nov 2017

Allergan to sell a quarter of its Teva stake in first quarter 2018

NEW YORK Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

07 Nov 2017

Valeant profit beats forecasts on Bausch & Lomb strength

Valeant Pharmaceuticals International Inc reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye care business, sending its shares up more than 15 percent.

01 Nov 2017

Allergan assuages shareholder fears over losing Restasis patent

Allergan Plc on Wednesday reassured shareholders that it would return to earnings growth in 2019 after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis. | Video

30 Oct 2017

Obamacare benchmark premiums up 37 percent in 2018 after subsidy cut-off

NEW YORK The average monthly premium for benchmark Obamacare insurance plans will surge around 37 percent in 2018, the U.S. Department of Health and Human Services said on Monday, fueled by the Trump administration's suspension of billions of dollars in subsidy payments to health insurers.

17 Oct 2017

New cancer drugs help Johnson & Johnson top profit estimates

Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.

16 Oct 2017

U.S. judge in Texas invalidates Allergan patents on Restasis

A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

13 Oct 2017

U.S. hospital, insurer stocks drop after Trump ends subsidies

NEW YORK Shares of U.S. hospital companies and health insurers fell on Friday after President Donald Trump said he would cut off Obamacare subsidies to health insurance companies for low-income patients, a move that could make healthcare less affordable next year for some people.

12 Oct 2017

Allergan settles with one of four companies contesting Restasis patent

Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court.

05 Oct 2017

Senator McCaskill drafts bill in response to Allergan patent maneuver

NEW YORK Democratic U.S. Senator Claire McCaskill on Thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block U.S. Patent and Trademark Office review of a patent.

05 Oct 2017

Senator McCaskill drafts bill in response to Allergan patent maneuver

NEW YORK, Oct 5 Democratic U.S. Senator Claire McCaskill on Thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block U.S. Patent and Trademark Office review of a patent.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,411.34 + 21.88 +0.30%
DAX 13,167.54 + 108.88 +0.83%
CAC 40 5,366.15 + 25.70 +0.48%
TR Europe 182.91 + 0.88 +0.48%
GBP/USD 1.3240 +0.05%
GBP/EUR 1.1271 -0.07%
EUR/USD 1.1745 +0.11%
Gold 1,274.60 +0.00 +0.00%
Oil 56.67 +0.25 +0.44%
Corn 345.50 +0.50 +0.14%